Lack of association of CYP1A1 polymorphism with prostate cancer susceptibility of Tunisian men.

Cytochrome P450 (CYP)1A1 gene polymorphism has been shown to be associated with several diseases. In this study, we evaluated the association between the polymorphism in the cytochrome P-450 (CYP)1A1 (CYP1A1) gene and genetic susceptibility to prostate cancer (PCa) in Tunisian men. One hundred and thirty eight PCa patients and the same number of controls were enrolled in this study.

CYP17 gene polymorphism and prostate cancer susceptibility in a Tunisian population.

Prostate cancer (PCa) formation has been reported to be associated with androgen. Two key steps in the sex steroid synthesis are mediated by the enzyme cytochrome P450c 17α which is encoded in the CYP17 gene. The A2 allele of the CYP17 gene has been thought to be associated with increased functional activity of this steroidogenic enzyme.

[Contribution of PSA and its density in the diagnosis and tracking of the prostate cancer].

Owing to the fact that prostate cancer is the second cause of death behind lung cancer, several diagnostic strategies have been introduced in the past years. Among these prostate specific antigen is widely acknowledged to be the simplest and routine clinical parameter the purpose of this study is to reveal the contribution of the prostate specific antigen (PSA) in the diagnosis and tracking of prostate cancer compared to the PSA density (PSAD). 182 unrelated Tunisian men divided in two groups were considered by this study.

Polymorphisms of glutathione-S-transferase M1 and T1 and prostate cancer risk in a Tunisian population.

Unlabelled: Several genes involved in the metabolism of carcinogenesis have been found to be polymorphic in the human population, and specific alleles are associated with increase risk of cancer of various sites. This study is focused on the polymorphic enzymes glutathione-S-transferase M1 (GSTM1) and T1 (GSTT1) that involved in the detoxification of many xenobiotics involved in the etiology of prostate cancer.

Objective: To evaluate whether GSTM1 and/or GSTT1 contribute to prostate cancer (CaP) etiology, we studied 110 incident CaP cases and 122 controls.